Inspire Medical Systems, Inc. Introduces Digital Health Tools with Launch of New App

Download as PDF

MINNEAPOLIS, Minnesota – June 3, 2020 – Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical
technology company focused on the development and commercialization of innovative and minimally invasive
solutions for patients with obstructive sleep apnea (“OSA”), announced today the introduction of the new Inspire
Sleep app.

“Especially during these challenging times, patients are looking for more convenient ways to learn about treatment
options and manage their sleep apnea. In addition, medical practices are prioritizing treatments that allow for
efficient telemedicine consults and follow-up visits. The Inspire Sleep app allows patients to learn about Inspire
therapy and connect them with an Inspire-trained physician, either in person or through telemedicine,” said Tim
Herbert, President and Chief Executive Officer of Inspire Medical Systems. “Once patients receive Inspire therapy,
the Inspire Sleep app will conveniently and efficiently guide patients through follow-up care. With Inspire cloud, our
platform designed for remote diagnostics and patient monitoring, and now the Inspire Sleep app, we have launched
the foundation of Inspire’s digital health solutions.”

“Inspire patient consults have been some of the easier visits to transition to telemedicine,” said Dr. Phillip Huyett,
MD, Clinical Associate, Division of Sleep Medicine and Surgery at Massachusetts Eye and Ear and Clinical
Instructor of Otolaryngology–Head and Neck Surgery at the Harvard Medical School. “The initial evaluation is
largely based on a patient’s obstructive sleep apnea history and discussing the available treatment options for them,
none of which requires travel or time off for an in-person visit. The Inspire Sleep app is a highly valuable electronic
tool that addresses the most common patient questions in a straightforward manner and is superior to the handouts
utilized during in-person visits. Longer-term, the interaction between the Inspire Sleep app and Inspire cloud will
improve the efficiency of patient management.”

Inspire has multiple additional digital health solutions in development that are aimed at improving patient outcomes
and medical practice efficiency. Future versions of the Inspire Sleep app will support clinical data collection, provide
earlier insight into patient adherence and outcomes, and share data automatically with the Inspire cloud.

The Inspire Sleep app is available now from the Google Play or Apple app stores.

About Inspire Medical Systems

Inspire is a medical technology company focused on the development and commercialization of innovative and
minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first
and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to
severe obstructive sleep apnea.

For additional information about Inspire, please visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements,
including, without limitation, statements regarding the expected benefits of the Inspire Sleep app and Inspire cloud
and future digital health solutions. In some cases, you can identify forward-looking statements by terms such as
‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’
‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or
other similar expressions, although not all forward-looking statements contain these words.

These forward-looking statements are based on management’s current expectations and involve known and
unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking
statements. Other important factors that could cause actual results, performance or achievements to differ
materially from those contemplated in this press release can be found under the captions “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2019, as updated in our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2020, and as such factors may be updated from time to time in our other filings with the
SEC, which are accessible on the SEC’s website at and the Investors page of our website at These and other important factors could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press release. Any such forward-looking statements
represent management’s estimates as of the date of this press release. While we may elect to update such forward-
looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do
so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time
means that actual events are bearing out as expressed or implied in such forward-looking statements. These
forward-looking statements should not be relied upon as representing our views as of any date subsequent to the
date of this press release.

Investor & Media Contact:
Bob Yedid
LifeSci Advisors
[email protected]